Search & Analyze

Marksans Pharma Ltd.

HealthcarePharmaceuticals & Drugs

www.marksanspharma.com BSE: 524404NSE: MARKSANS

₹316.50BSE1.88%

16 Sep, 4:01 PM

₹316.50

₹14.34K Cr

27.76

4.51

15.31%

₹323.70

₹307.05

₹349.70

₹156.00

Customise metrics bar

Price Performance

Peer Comparison

Name
SUN PHARMA. SUNPHARMA	1,853.50	36.77	4,44,716.74	0.86	2,901.23	26.53%	15,299.88	10.46%	19.11
DIVI'S LAB. DIVISLAB	9,199.70	83.50	2,44,223.13	0.33	902.00	65.50%	3,080.00	27.80%	21.51
TORRENT PHAR TORNTPHARM	4,823.05	84.11	1,83,453.32	0.79	566.00	3.28%	4,921.00	54.85%	19.27
ZYDUSLIFE ZYDUSLIFE	1,105.00	24.42	1,10,224.17	0.09	990.20	-34.90%	8,017.00	21.96%	21.39
CIPLA LTD. CIPLA	1,359.75	32.59	1,09,848.55	0.96	785.55	-39.18%	7,119.28	2.33%	16.00
LAURUSLABS LAURUSLABS	1,906.00	94.19	1,02,983.51	0.10	362.07	123.94%	2,026.31	29.10%	18.20
DR.REDDY'S DRREDDY	1,145.25	29.67	95,591.76	0.70	435.60	-69.10%	8,099.80	-5.51%	13.75
Marksans Pharma Ltd. MARKSANS	316.50	27.76	14,342.63	0.28	159.41	173.89%	840.80	35.61%	21.10

Quarterly Results

consolidated figures in ₹ Crores · Quarterly

Particulars	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	560.01	590.62	641.92	681.85	708.46	619.99	720.41	754.43	856.11	840.80
Expenses	450.37	462.18	495.11	551.35	581.52	519.87	575.92	593.69	660.69	627.76
	109.64	128.44	146.81	130.50	126.93	100.12	144.49	160.74	195.42	213.03
	19.58%	21.75%	22.87%	19.14%	17.92%	16.15%	20.06%	21.31%	22.83%	25.34%
	16.53	14.95	-0.07	36.11	15.34	5.64	21.57	20.14	35.17	25.40
Interest	4.84	2.92	2.63	2.67	3.44	6.06	5.81	5.94	6.31	7.00
	21.06	20.44	19.51	20.69	22.74	23.10	26.92	24.33	24.29	24.86
	100.28	120.02	124.60	143.26	116.09	76.60	133.33	150.62	200.00	206.57
	22.57%	25.79%	21.54%	26.66%	21.85%	24.02%	25.65%	24.52%	25.48%	22.83%
	78.29	88.75	96.72	104.56	90.55	58.32	98.25	113.20	148.13	157.17
	1.73	1.96	2.13	2.31	2.00	1.29	2.17	2.50	3.27	3.47

Profit & Loss

consolidated figures in ₹ Crores · Annual

Particulars	FY 2021-22 (Mar)	FY 2022-23 (Mar)	FY 2023-24 (Mar)	FY 2024-25 (Mar)	FY 2025-26 (Mar)
No of Months	12.00	12.00	12.00	12.00	12.00
INCOME :
	1,548.88	2,039.52	2,289.55	2,746.61	3,037.90
	1,490.84	1,852.14	2,177.41	2,622.85	2,950.94
EXPENDITURE :
Increase/Decrease in Stock	12.90	-6.39	-73.86	-183.76	-136.42
Raw Material Consumed	703.92	927.75	1,111.98	1,327.50	1,413.70
Power & Fuel Cost	18.59	24.50	36.94	40.08	54.08
Employee Cost	220.30	239.37	293.64	350.30	420.93
Other Manufacturing Expenses	12.73	96.48	94.76	140.08	155.88
General and Administration Expenses	37.74	52.79	93.90	117.60	109.99
Selling and Distribution Expenses	119.05	133.19	127.31	256.64	260.26
Miscellaneous Expenses	106.73	45.14	34.16	41.72	71.74
	1,231.96	1,512.82	1,718.83	2,090.16	2,350.16
Operating Profit (Excl OI)	258.88	339.32	458.58	532.68	600.78
	41.85	59.31	50.42	66.33	82.53
	300.73	398.63	509.00	599.01	683.31
Interest	8.45	9.13	11.20	11.66	24.13
PBDT	292.29	389.51	497.80	587.35	659.19
	44.78	51.85	74.27	83.39	98.63
Profit Before Taxation & Exceptional Items	247.51	337.65	423.53	503.97	560.56
	247.51	337.65	423.53	503.97	560.56
Provision for Tax	60.70	72.33	108.63	121.35	140.49
	186.81	265.32	314.90	382.62	420.06
Extra items				0.00	0.00
Minority Interest	-2.25	0.99	-1.20	-2.04	-2.16
Consolidated Net Profit	184.57	266.31	313.70	380.58	417.90
Profit Balance B/F	334.93	509.31	777.60	1,068.93	1,422.01
Appropriations	519.50	775.62	1,091.30	1,449.50	1,839.91
Equity Dividend %	25.00%	50.00%	60.00%	80.00%	90.00%
	4.51	5.88	6.92	8.40	9.22
Adjusted EPS	4.51	5.88	6.92	8.40	9.22

Balance Sheet

consolidated figures in ₹ Crores

Particulars	FY 2021-22 (Mar)	FY 2022-23 (Mar)	FY 2023-24 (Mar)	FY 2024-25 (Mar)	FY 2025-26 (Mar)
	40.93	45.32	45.32	45.32	45.32
Share Warrants & Outstandings	93.10				3.34
Total Reserves	1,068.24	1,699.85	2,019.74	2,421.60	2,974.50
Reserve excluding Revaluation Reserve	1,068.24	1,699.85	2,019.74	2,421.60	2,974.50
	1,202.27	1,745.16	2,065.05	2,466.91	3,023.16
Minority Interest	20.70	19.91	20.85	22.47	29.52
Deferred Tax Assets / Liabilities	13.76	15.39	10.62	3.66	-7.88
Other Long Term Liabilities	41.43	65.69	190.02	263.33	270.13
Long Term Provisions	1.86	3.25	4.56	5.92	5.92
Total Non-Current Liabilities	57.05	84.33	205.20	272.91	268.17
Trade Payables	200.08	230.60	268.28	305.70	336.91
Other Current Liabilities	96.80	42.20	70.62	117.17	118.69
Short Term Borrowings	41.29	41.59	29.09	23.09	29.59
Short Term Provisions	41.92	26.60	21.86	31.39	41.90
Total Current Liabilities	380.08	340.99	389.85	477.34	527.09
Total Liabilities	1,660.11	2,190.39	2,680.95	3,239.63	3,847.94
Gross Block	726.27	828.26	1,134.80	1,413.02	1,605.35
Less: Accumulated Depreciation	297.96	341.95	358.87	431.06	561.24
Net Block	428.31	486.31	775.94	981.96	1,044.11
Capital Work in Progress	0.70	7.25	5.38	9.00	14.78
Long Term Loans & Advances	4.16	18.91	32.94	26.27	22.50
Other Non Current Assets			0.17	0.17	0.01
Total Non-Current Assets	435.04	515.09	818.46	1,035.51	1,125.20
Currents Investments	0.44	0.54	26.99	0.74
Inventories	424.44	484.74	617.94	845.52	972.28
Sundry Debtors	394.78	416.85	453.18	540.04	644.57
Cash and Bank	349.27	714.96	673.58	704.21	989.65
Other Current Assets	24.36	22.74	30.98	32.41	40.20
Short Term Loans and Advances	31.79	35.48	59.82	81.20	76.05
Total Current Assets	1,225.07	1,675.30	1,862.49	2,204.12	2,722.74
Net Current Assets (Including Current Investments)	844.98	1,334.31	1,472.64	1,726.78	2,195.65
Total Assets	1,660.11	2,190.39	2,680.95	3,239.63	3,847.94
Contingent Liabilities	1.45	1.45
Total Debt	41.29	41.59	29.09	23.09	29.59
	27.10	38.51	45.57	54.44	66.64
Adjusted Book Value	27.10	38.51	45.57	54.44	66.64

Cash Flow

consolidated figures in ₹ Crores

Particulars	FY 2021-22 (Mar)	FY 2022-23 (Mar)	FY 2023-24 (Mar)	FY 2024-25 (Mar)	FY 2025-26 (Mar)
No of Months	12.00	12.00	12.00	12.00	12.00
	247.51	337.65	423.53	503.97	560.56
Adjustment	35.31	74.24	55.42	69.37	99.68
Changes In working Capital	-110.70	-111.47	-126.19	-240.77	-62.46
Cash Flow after changes in Working Capital	172.12	300.43	352.76	332.56	597.78
Cash Flow from Operating Activities	99.26	237.41	230.41	206.66	458.13
Cash Flow from Investing Activities	-84.39	-259.21	-140.84	-49.01	-248.27
Cash Flow from Financing Activitie	79.51	197.83	-68.73	-65.15	-70.93
Net Cash Inflow / Outflow	94.38	176.03	20.84	92.51	138.93
Opening Cash & Cash Equivalents	112.03	206.41	382.44	403.28	495.79
Effect of Foreign Exchange Fluctuations		0.00			-0.58
Closing Cash & Cash Equivalent	206.41	382.44	403.28	495.79	634.14

Ratios

Valuation

27.76

4.51

16.40

4.52

11.40

70.16

Profitability

15.31

21.10

11.85

19.78

13.83

Leverage & Liquidity

0.01

5.17

24.24

Returns

0.28

0.86

Shareholding Pattern

Numbers in percentages

Particulars	Jun '24	Sep '24	Dec '24	Mar '25	Jun '25	Sep '25	Dec '25	Mar '26	Jun '26
	43.87	43.87	43.87	43.87	43.87	43.87	43.87	43.87	43.87
	22.34	25.41	26.26	26.76	25.38	22.20	14.03	23.33	23.66
	33.78	30.71	29.87	29.37	30.75	33.93	42.09	32.79	32.47
	56.13	56.13	56.13	56.13	56.13	56.13	56.13	56.13	56.13
No. of Shareholders	2,35,500	2,48,845	2,59,813	2,57,273	2,56,221	2,65,788	2,55,153	2,46,279	2,46,635

Corporate Actions

Showing: All

Date	Type	Details	Ex-Date	Record Date
2026-07-31	Board Meeting	Quarterly Results
2026-07-03	AGM
2026-05-26	Ex Dividend	Rs.0.9000 per share(90%)Final Dividend	2026-08-20	2026-08-20

Insider Trading

Date	Person	Category	Transaction Type	Shares	Value (₹)

No insider trading data available.

Sector Overview

HealthcarePharmaceuticals & Drugs

Marksans Pharma Ltd. operates in the Healthcare sector under the Pharmaceuticals & Drugs industry. This sector is one of the key drivers of the Indian economy and is closely tracked by the relevant Nifty sectoral index.

Company Profile

Corporate information and contact details

Key Management

9 members across the board and senior leadership

Harshavardhan Panigrahi

Company Secretary & Compliance Officer

—

Mark Saldanha

Chairman & Managing Director

₹6.41 Cr

Mar '26

Sandra Saldanha

Whole Time Director

₹70.69 L

Mar '26

Varddhman Vikramaditya Jain

Whole Time Director

₹2.63 Cr

Mar '26

Digant Mahesh Parikh

Non Executive Independent Director

₹5.00 L

Mar '26

Abhinna Sundar Mohanty

Non Executive Independent Director

₹3.10 L

Mar '26

Shailaja Vardhan

Non Executive Independent Director

₹5.00 L

Mar '26

Srinivas Mishra

Non Executive Independent Director

₹4.00 L

Mar '26

Sunny Sharma

Non Independent & Non Executive Director

—

MARKSANS Latest News

News

10 of 10 articles

EQUITY7 Sept 2026 · 15:36

Marksans Pharma informs about press release

EQUITY12 Aug 2026 · 16:48

Marksans Pharma informs about outcome of board meeting

EQUITY12 Aug 2026 · 14:36

Marksans Pharma shines on reporting near three-fold jump in Q1 consolidated net profit

The total consolidated income of the company has increased by 38.45% at Rs 866.20 crore for Q1FY27

COMPANY12 Aug 2026 · 14:28

Marksans Pharma reports near three-fold jump in Q1 consolidated net profit

The total consolidated income of the company has increased by 38.45% at Rs 866.20 crore for Q1FY27

EQUITY4 Aug 2026 · 17:36

Marksans Pharma informs about AGM

EQUITY4 Aug 2026 · 14:32

Marksans Pharma informs about annual report

EQUITY8 Jul 2026 · 11:36

Marksans Pharma surges on inking pact to acquire 100% stake in ABCnow GmbH

The acquisition is expected to be completed by July 31, 2026

COMPANY8 Jul 2026 · 11:19

Marksans Pharma inks pact to acquire 100% stake in ABCnow GmbH

The acquisition is expected to be completed by July 31, 2026

EQUITY8 Jul 2026 · 10:26

Marksans Pharma informs about acquisition

EQUITY26 May 2026 · 13:13

Marksans Pharma reports Profit after tax of Rs 919.23 Mln, in the March 2026 quarter

MARKSANS

₹316.50

+1.88%